These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18458264)

  • 1. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?
    Hernandez AF; Harrington RA
    CMAJ; 2008 May; 178(10):1316-9. PubMed ID: 18458264
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.
    Pilote L; Abrahamowicz M; Eisenberg M; Humphries K; Behlouli H; Tu JV
    CMAJ; 2008 May; 178(10):1303-11. PubMed ID: 18458262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors in heart failure: effect on mode of death.
    Kübler W
    Eur Heart J; 1997 Jan; 18(1):3-4. PubMed ID: 9049504
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
    Seeland U; Kouchi I; Zolk O; Jockenhövel F; Itter G; Linz W; Böhm M
    Eur J Heart Fail; 2003 Jun; 5(3):241-6. PubMed ID: 12798820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
    Costantino S; Millozzi F; Scarlata S
    Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
    [No Abstract]   [Full Text] [Related]  

  • 6. Can ACE inhibitor therapy prevent end-stage renal failure?
    Craig JC
    Med J Aust; 2001 Sep; 175(5):276. PubMed ID: 11587263
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].
    Kardiologiia; 2008; 48(11):64-8. PubMed ID: 19076083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.
    Garg R; Yusuf S
    JAMA; 1995 May; 273(18):1450-6. PubMed ID: 7654275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
    Shah AD; Arora RR
    Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
    Shah AD; Arora RR
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):281-3. PubMed ID: 16382264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?
    Francis GS; Gassler JP
    Cleve Clin J Med; 2001 Mar; 68(3):185-6. PubMed ID: 11263844
    [No Abstract]   [Full Text] [Related]  

  • 16. Mega-trials: is meta-analysis an alternative?
    Lubsen J
    Eur J Clin Pharmacol; 1996; 49 Suppl 1():S29-33. PubMed ID: 8834929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.
    Lubsen J; Chadha DR; Yotof YT; Swedberg K
    Am J Cardiol; 1996 Jun; 77(14):1191-6. PubMed ID: 8651094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
    Cressman AM; Macdonald EM; Fernandes KA; Gomes T; Paterson JM; Mamdani MM; Juurlink DN;
    Br J Clin Pharmacol; 2015 Oct; 80(4):662-9. PubMed ID: 25980448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.